Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Price, Angie
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, )	Recruiting	3	450	Europe, US, RoW	Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio	Evopoint Biosciences Inc.	Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia	04/25	12/25
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome	Active, not recruiting	3	505	Europe, Canada, Japan, US, RoW	VAY736, Placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Sjogren Syndrome	05/25	05/27
NCT02995252: The HOPE Study: Characterizing Patients With Hepatitis B and C	Recruiting	N/A	550	US	Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy	University of Maryland, Baltimore	Hepatitis B， Chronic, Hepatitis C	01/25	12/25